Peytant Solutions, Inc. (PSI) plans for the first application of its patented technology combining collagen with stenting technology to be for the treatment of tracheobronchial structures caused by malignancy. PSI plans to use collagen obtained from human amniotic membrane to cover a self-expanding Nitinol stent. This application PSI technology will require clearance by the U.S. Food and Drug Administration before use in patients can start.
